Skip to main content

Advertisement

Log in

Pharmacotherapy of Opioid Addiction: “Putting a Real Face on a False Demon”

  • Proceedings
  • Published:
Journal of Medical Toxicology Aims and scope Submit manuscript

Abstract

Methadone maintenance therapy (MMT), a pharmacological treatment for opioid use disorder for the past 50 years, continues to remain controversial. Despite consistent and overwhelming evidence confirming the effectiveness and safety of MMT, misconceptions and myths persist regarding its legitimacy as a treatment for opioid addiction. This often results in the underutilization and limited availability of this treatment modality. Despite successful outcomes, the controversial nature of MMT, and the stigma experienced by the patients on methadone, has been a particularly difficult obstacle to overcome. We present the history of MMT, review the evidence for its efficacy in the treatment of opioid dependence, and explore the origins of the stigma and misconceptions related to MMT.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Federal Narcotic Farm. Cal West Med, 1935. 42 (3): p. 228-9.

  2. Administration, S.A.a.M.H.S. Federal guidelines for opioid treatment programs. Rockville: Substance Abuse and Mental Health Services Administration; 2015.

    Google Scholar 

  3. Control, U.S.D.o.J.O.o.D. Title 21 Code of Federal Regulations Part 1306: Prescriptions. 2015 [cited 2015 7/18/2015].

  4. Courtwright DT. The prepared mind: Marie Nyswander, methadone maintenance, and the metabolic theory of addiction. Addiction. 1997;92(3):257–65.

    Article  CAS  PubMed  Google Scholar 

  5. Alcoholism, N.Y.O.o. and S.A. Services, methadone treatment works: a compendium for methadone maintenance treatment. 1994: New York State Office of Alcoholism and Substance Abuse Services.

  6. Dole VP, Nyswander M. A medical treatment for diacetylmorphine (heroin) addiction. A clinical trial with methadone hydrochloride. JAMA. 1965;193:646–50.

    Article  CAS  PubMed  Google Scholar 

  7. Stimmel B, Kreek MJ. Neurobiology of addictive behaviors and its relationship to methadone maintenance. Mt Sinai J Med. 2000;67(5-6):375–80.

    CAS  PubMed  Google Scholar 

  8. Kaufman MJ et al. Cerebral phosphorus metabolite abnormalities in opiate-dependent polydrug abusers in methadone maintenance. Psychiatry Res. 1999;90(3):143–52.

    Article  CAS  PubMed  Google Scholar 

  9. Langleben DD et al. Acute effect of methadone maintenance dose on brain FMRI response to heroin-related cues. Am J Psychiatry. 2008;165(3):390–4.

    Article  PubMed  Google Scholar 

  10. Sees KL et al. Methadone maintenance vs 180-day psychosocially enriched detoxification for treatment of opioid dependence: a randomized controlled trial. JAMA. 2000;283(10):1303–10.

    Article  CAS  PubMed  Google Scholar 

  11. Nicholls L, Bragaw L, Ruetsch C. Opioid dependence treatment and guidelines. J Manag Care Pharm. 2010;16(1 Suppl B):S14–21.

    PubMed  Google Scholar 

  12. Kreek MJ et al. Methadone use in patients with chronic renal disease. Drug Alcohol Depend. 1980;5(3):197–205.

    Article  CAS  PubMed  Google Scholar 

  13. Atkinson TJ, Fudin J., Wegrzyn EL, Bettinger JJ. Dialysis, opioids, and pain management: where’s the evidence? Practical Pain Management, 2014. 1-14.

  14. Krambeer LL et al. Methadone therapy for opioid dependence. Am Fam Physician. 2001;63(12):2404–10.

    CAS  PubMed  Google Scholar 

  15. Centers for Disease, C. and Prevention. Vital signs: risk for overdose from methadone used for pain relief—United States, 1999-2010. MMWR Morb Mortal Wkly Rep. 2012;61(26):493–7.

    Google Scholar 

  16. Chou R et al. Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. J Pain. 2009;10(2):113–30.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Medicine, t.A.A.o.P. The evidence against methadonea as a “Preferred” analgesic: a position statement from the American Academy of Pain Medicine. 2014. the American Academy of Pain Medicine.

  18. Justo D et al. Methadone-associated Torsades de Pointes (polymorphic ventricular tachycardia) in opioid-dependent patients. Addiction. 2006;101(9):1333–8.

    Article  PubMed  Google Scholar 

  19. Katchman AN et al. Influence of opioid agonists on cardiac human ether-a-go-go-related gene K (+) currents. J Pharmacol Exp Ther. 2002;303(2):688–94.

    Article  CAS  PubMed  Google Scholar 

  20. Bliesener N et al. Plasma testosterone and sexual function in men receiving buprenorphine maintenance for opioid dependence. J Clin Endocrinol Metab. 2005;90(1):203–6.

    Article  CAS  PubMed  Google Scholar 

  21. Hallinan R et al. Erectile dysfunction in men receiving methadone and buprenorphine maintenance treatment. J Sex Med. 2008;5(3):684–92.

    Article  CAS  PubMed  Google Scholar 

  22. Kreek MJ. Rationale for maintenance pharmacotherapy of opiate dependence. Res Publ Assoc Res Nerv Ment Dis. 1992;70:205–30.

    CAS  PubMed  Google Scholar 

  23. Gottheil E, Sterling RC, Weinstein SP. Diminished illicit drug use as a consequence of long-term methadone maintenance. J Addict Dis. 1993;12(4):45–57.

    Article  CAS  PubMed  Google Scholar 

  24. Gronbladh L, Ohlund LS, Gunne LM. Mortality in heroin addiction: impact of methadone treatment. Acta Psychiatr Scand. 1990;82(3):223–7.

    Article  CAS  PubMed  Google Scholar 

  25. Ball JC, Ross A. The effectiveness of methadone maintenance treatment. New York: Springer Verlag; 1991.

    Book  Google Scholar 

  26. Kleber HD. Methadone maintenance 4 decades later: thousands of lives saved but still controversial. JAMA. 2008;300(19):2303–5.

    Article  CAS  PubMed  Google Scholar 

  27. Novick DM et al. Absence of antibody to human immunodeficiency virus in long-term, socially rehabilitated methadone maintenance patients. Arch Intern Med. 1990;150(1):97–9.

    Article  CAS  PubMed  Google Scholar 

  28. Metzger DS et al. Human immunodeficiency virus seroconversion among intravenous drug users in- and out-of-treatment: an 18-month prospective follow-up. J Acquir Immune Defic Syndr. 1993;6(9):1049–56.

    CAS  PubMed  Google Scholar 

  29. Des Jarlais DC et al. HIV-1 infection among intravenous drug users in Manhattan, New York City, from 1977 through 1987. JAMA. 1989;261(7):1008–12.

    Article  CAS  PubMed  Google Scholar 

  30. Novick DM et al. Methadone maintenance patients in general medical practice. A preliminary report. JAMA. 1988;259(22):3299–302.

    Article  CAS  PubMed  Google Scholar 

  31. Novick DM, Salsitz EA, Joseph H, Kreek MJ. Methadone medical maintenance: an early twenty-first century perspective. J Addict Dis. 2015;34(2-3):226–37.

    Article  PubMed  Google Scholar 

  32. Salsitz EA et al. Methadone medical maintenance (MMM): treating chronic opioid dependence in private medical practice—a summary report (1983-1998). Mt Sinai J Med. 2000;67(5-6):388–97.

    CAS  PubMed  Google Scholar 

  33. Lawlor J. Many resist LePage administration’s bid to drop methadone as MaineCare benefit. Portland Press Herald: Portland, Maine; 2015.

    Google Scholar 

  34. Bukten A et al. Engagement with opioid maintenance treatment and reductions in crime: a longitudinal national cohort study. Addiction. 2012;107(2):393–9.

    Article  PubMed  Google Scholar 

  35. Krupitsky E et al. Injectable extended-release naltrexone for opioid dependence: a double-blind, placebo-controlled, multicentre randomised trial. Lancet. 2011;377(9776):1506–13.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to T. Wiegand.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Salsitz, E., Wiegand, T. Pharmacotherapy of Opioid Addiction: “Putting a Real Face on a False Demon”. J. Med. Toxicol. 12, 58–63 (2016). https://doi.org/10.1007/s13181-015-0517-5

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13181-015-0517-5

Keywords

Navigation